Pharmacovigilance and Drug Safety Software Market Size, Share, Growth, and Industry Analysis, By Type (ADR Reporting Software, Drug Safety Audits Software,Issue Tracking Software,Fully Integrated Software), By Application (Pharma and Biotech Companies,Contract Research Organizations (CROs),Business Process Outsourcing (BPO) Firms,Other Pharmacovigilance Service Providers), Regional Insights and Forecast to 2035

Pharmacovigilance and Drug Safety Software Market Overview

The global Pharmacovigilance and Drug Safety Software Market size is projected to grow from USD 17439.81 million in 2026 to USD 19065.2 million in 2027, reaching USD 38887.68 million by 2035, expanding at a CAGR of 9.32% during the forecast period.

The pharmacovigilance and drug safety software market is expanding rapidly, with over 74% of global pharmaceutical companies deploying at least one pharmacovigilance software solution by 2024. More than 48,000 adverse drug reaction (ADR) reporting systems are active worldwide, covering 140+ countries. The adoption of cloud-based and fully integrated solutions has risen by 61% over the past three years. In 2024, over 1.2 billion patient safety reports were processed through such platforms globally, driven by stringent drug safety regulations in over 90% of developed markets.

The USA accounts for 38% of the global pharmacovigilance and drug safety software market, with over 19,000 operational systems across pharmaceutical, biotech, and CRO sectors. The FDA’s FAERS database processed over 2.2 million individual case safety reports in 2024, of which 67% originated from automated software submissions. More than 80% of top-tier pharma companies in the USA use fully integrated safety platforms with AI-assisted signal detection. Cloud-based solutions represent 53% of US adoption, driven by scalability needs and multi-site data accessibility.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 78% of large pharmaceutical companies cite regulatory compliance as the primary driver for adopting pharmacovigilance software.
• Major Market Restraint: 42% of small to mid-sized pharma firms identify high licensing costs as a barrier to adoption.
• Emerging Trends: 66% of new solutions in 2024 include AI-based predictive analytics for ADR detection.
• Regional Leadership: North America accounts for 41% of the global market share.
• Competitive Landscape: The top five vendors control 53% of total deployments worldwide.
• Market Segmentation: Fully integrated software makes up 46% of installations globally.
• Recent Development: 58% of launches between 2023–2024 are cloud-first platforms.

Pharmacovigilance and Drug Safety Software Market Latest Trends

The market is evolving with significant emphasis on AI and big data analytics, enabling faster ADR detection and regulatory reporting. In 2024, AI-enhanced pharmacovigilance systems processed 27% more safety cases per analyst compared to traditional platforms. Integration with electronic health records (EHR) is now present in 71% of newly deployed systems, improving real-time case collection from hospitals and clinics. Cloud-based deployments increased to 61% of all installations, supporting scalability for companies handling over 500,000 safety reports annually. A key trend is automation in periodic safety update report (PSUR) generation, with over 45% of systems providing automated PSUR templates. Additionally, mobile pharmacovigilance apps are growing, with over 3.1 million healthcare professionals and patients submitting ADRs directly via mobile platforms in 2024.

Pharmacovigilance and Drug Safety Software Market Dynamics

DRIVER

"Rising volume of adverse event reports worldwide."

Over 20 million new ADR reports were recorded globally in 2024, a 19% increase from 2022. Regulatory bodies in over 120 countries mandate electronic submission of safety data, boosting demand for automation. The WHO’s global drug safety database now contains over 37 million case reports, underscoring the need for efficient processing tools.

RESTRAINT

" High software implementation and maintenance costs."

Initial licensing fees for enterprise pharmacovigilance platforms range from USD 250,000 to over USD 1 million, excluding annual maintenance costs of 15–20%. This pricing structure limits adoption among smaller CROs and mid-sized pharma companies, where 42% still rely on partially manual systems.

OPPORTUNITY

" Expansion of personalized medicine and rare disease drug pipelines."

Over 7,000 rare disease drugs are in global development pipelines, each requiring intensive safety monitoring. Personalized therapies, accounting for 28% of FDA approvals in 2024, demand specialized safety tracking. Software vendors have the opportunity to offer niche modules for gene therapy, cell therapy, and biologics monitoring.

CHALLENGE

"Interoperability with diverse healthcare IT ecosystems."

Globally, over 250 EHR systems and 80 regulatory submission formats exist, creating integration challenges. Approximately 35% of pharma companies report delays in data migration when switching platforms, impacting timely safety submissions.

Pharmacovigilance and Drug Safety Software Market Segmentation

The market is divided by software type and application, with fully integrated platforms gaining momentum due to efficiency in compliance workflows.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

ADR Reporting Software: ADR reporting systems account for 28% of deployments, with over 13,000 active installations globally in 2024. These systems handle initial case entry, follow-ups, and regulatory submission in ICH E2B format.

In 2025, ADR Reporting Software is valued at USD 5,103.46 million, representing 32.0% of the global pharmacovigilance and drug safety software market. It is projected to grow at a CAGR of 9.1% to 2034, fueled by the growing need for automated adverse drug reaction reporting, real-time data capture, and integration with electronic health records. Regulatory requirements in major markets are pushing pharmaceutical companies and healthcare institutions to adopt specialized reporting platforms to improve compliance, speed of case processing, and accuracy in adverse event documentation.

Top 5 Major Dominant Countries in the ADR Reporting Software Segment

• United States: USD 1,071.73 million in 2025, 21.0% share, 8.9% CAGR, driven by FDA-mandated adverse event reporting and seamless linkage with EHR platforms.
• China: USD 867.59 million in 2025, 17.0% share, 9.4% CAGR, boosted by biopharma expansion and government-supported pharmacovigilance programs.
• Germany: USD 561.38 million in 2025, 11.0% share, 9.0% CAGR, with strong demand from regulatory-compliant pharma operations.
• Japan: USD 510.35 million in 2025, 10.0% share, 9.2% CAGR, supported by hospital-based PV systems and safety automation. India: USD 459.31 million in 2025, 9.0% share, 9.6% CAGR, benefiting from centralized PV centers and outsourced safety reporting services.

Drug Safety Audits Software: Comprising 14% of installations, audit software supports over 6,500 companies in ensuring compliance with GVP (Good Pharmacovigilance Practices) guidelines.

Drug Safety Audits Software is projected at USD 3,349.13 million in 2025, accounting for 21.0% of the market and growing at a CAGR of 9.4% through 2034. Its adoption is being driven by the need to ensure compliance in pharmaceutical manufacturing, distribution, and post-market drug surveillance. The software enables companies to maintain GMP audit trails, manage inspection readiness, and ensure quality control in both clinical and commercial stages.

Top 5 Major Dominant Countries in the Drug Safety Audits Software Segment

• United States: USD 703.32 million in 2025, 21.0% share, 9.2% CAGR, with wide use in GMP compliance and quality control systems.
• China: USD 603.84 million in 2025, 18.0% share, 9.5% CAGR, growing with adoption in pharma QA departments.
• Germany: USD 469.94 million in 2025, 14.0% share, 9.1% CAGR, driven by EU pharmacovigilance audit requirements.
• Japan: USD 368.40 million in 2025, 11.0% share, 9.3% CAGR, used in trial monitoring and manufacturing audits.
• India: USD 334.91 million in 2025, 10.0% share, 9.8% CAGR, supported by CRO/BPO-led audit services.

Issue Tracking Software: Making up 12% of deployments, these systems are used by 5,800+ organizations to track safety-related operational tasks and CAPA (Corrective and Preventive Actions). Its ability to centralize adverse event tracking and integrate with global safety databases makes it critical for multinational drug safety teams.

In 2025, Issue Tracking Software holds USD 2,552.48 million in value, representing 16.0% of the global market, and is projected to expand at a 9.5% CAGR to 2034. This software is integral to real-time safety case management, workflow monitoring, and ensuring timely resolution of regulatory compliance issues in pharmacovigilance systems. Its ability to centralize adverse event tracking and integrate with global safety databases makes it critical for multinational drug safety teams.

Top 5 Major Dominant Countries in the Issue Tracking Software Segment

• United States: USD 510.50 million in 2025, 20.0% share, 9.3% CAGR, with integration into global safety reporting frameworks.
• China: USD 459.44 million in 2025, 18.0% share, 9.7% CAGR, boosted by growth in PV outsourcing companies.
• Germany: USD 357.35 million in 2025, 14.0% share, 9.4% CAGR, used extensively in EU-regulated safety environments.
• Japan: USD 280.77 million in 2025, 11.0% share, 9.5% CAGR, for adverse reaction case management.
• India: USD 255.25 million in 2025, 10.0% share, 9.9% CAGR, gaining traction in outsourced PV process workflows.

Fully Integrated Software: Dominating with 46% share, fully integrated suites manage case intake, signal detection, regulatory reporting, and analytics. Over 21,000 companies use such systems in 2024. Large pharmaceutical and biotech firms increasingly prefer integrated solutions to manage the entire safety lifecycle within one environment, ensuring seamless compliance across multiple regions.

Fully Integrated Software is valued at USD 6,947.92 million in 2025, making up 31.0% of the global market, and is expected to grow at a 9.2% CAGR to 2034. It offers end-to-end functionality for case processing, signal detection, regulatory reporting, and analytics in a single platform, reducing operational silos and improving efficiency.

Top 5 Major Dominant Countries in the Fully Integrated Software Segment

• United States: USD 1,456.06 million in 2025, 21.0% share, 9.0% CAGR, widely used for global PV operations and lifecycle safety management.
• China: USD 1,249.03 million in 2025, 18.0% share, 9.4% CAGR, adopted by leading domestic pharma manufacturers.
• Germany: USD 973.82 million in 2025, 14.0% share, 9.1% CAGR, deployed in multinational pharmaceutical companies.
• Japan: USD 764.27 million in 2025, 11.0% share, 9.3% CAGR, applied in both clinical and post-market safety systems.
• India: USD 694.79 million in 2025, 10.0% share, 9.6% CAGR, favored by CROs and BPOs for large-scale PV projects.

BY APPLICATION

Pharma and Biotech Companies: Representing 53% of demand, with over 24,000 installations worldwide in 2024.

Pharma and Biotech Companies are valued at USD 8,773.67 million in 2025, accounting for 55.0% of the global market, with a CAGR of 9.3% to 2034. The segment leads adoption due to stringent regulatory frameworks, high-volume clinical trial data processing, and integration with global pharmacovigilance systems for both pre-market and post-market safety.

Top 5 Major Dominant Countries in the Pharma and Biotech Companies Application

• United States: USD 1,930.21 million in 2025, 22.0% share, 9.1% CAGR, leading in advanced PV automation and global trial safety networks.
• China: USD 1,579.26 million in 2025, 18.0% share, 9.5% CAGR, expanding with domestic biotech manufacturing scale-up.
• Germany: USD 1,140.58 million in 2025, 13.0% share, 9.2% CAGR, driven by EU compliance and multinational pharma hubs.
• Japan: USD 964.10 million in 2025, 11.0% share, 9.3% CAGR, supported by advanced hospital-linked PV systems.
• India: USD 789.63 million in 2025, 9.0% share, 9.7% CAGR, boosted by outsourced PV and regulatory services.

Contract Research Organizations (CROs): Account for 21% of demand, handling outsourced safety case processing for over 300 global drug developers.

Contract Research Organizations (CROs) hold USD 3,032.07 million in 2025, representing 19.0% of the market, and are projected to grow at 9.4% CAGR to 2034. CROs rely heavily on PV software for large-scale trial management, safety case reporting, and multi-country regulatory submissions.

Top 5 Major Dominant Countries in the CRO Application

• United States: USD 636.73 million in 2025, 21.0% share, 9.2% CAGR, driven by full-service CRO adoption of integrated PV platforms.
• China: USD 545.77 million in 2025, 18.0% share, 9.6% CAGR, with a surge in outsourced global clinical trials.
• Germany: USD 424.49 million in 2025, 14.0% share, 9.3% CAGR, specializing in niche therapy PV services.
• Japan: USD 333.53 million in 2025, 11.0% share, 9.4% CAGR, focusing on safety reporting for Asia-based trials.
• India: USD 303.21 million in 2025, 10.0% share, 9.8% CAGR, leading in low-cost PV outsourcing for western pharma.

Business Process Outsourcing (BPO) Firms: Make up 16% of the market, providing cost-efficient safety data management for generic and specialty drug makers.

BPO Firms are projected at USD 2,712.01 million in 2025, accounting for 17.0% of the global market, with a CAGR of 9.5% to 2034. This segment thrives on end-to-end PV process handling, case data entry, medical review, and compliance reporting for global clients.

Top 5 Major Dominant Countries in the BPO Firms Application

• United States: USD 542.40 million in 2025, 20.0% share, 9.3% CAGR, for outsourced PV support from domestic and offshore teams.
• China: USD 487.08 million in 2025, 18.0% share, 9.7% CAGR, offering bilingual PV documentation and regulatory compliance services.
• Germany: USD 379.68 million in 2025, 14.0% share, 9.4% CAGR, delivering PV outsourcing for EU pharma.
• Japan: USD 298.32 million in 2025, 11.0% share, 9.5% CAGR, focusing on hybrid in-house and outsourced models.
• India: USD 271.20 million in 2025, 10.0% share, 9.9% CAGR, dominating in global PV processing for large pharma.

Other Pharmacovigilance Service Providers: Cover 10% of installations, including academic research centers and regulatory agencies.

Other Pharmacovigilance Service Providers account for USD 1,435.24 million in 2025, making up 9.0% of the market, and are projected to expand at a 9.6% CAGR to 2034. This group includes independent safety consultancies, regulatory advisors, and health-tech PV service startups.

Top 5 Major Dominant Countries in the Other Service Providers Application

• United States: USD 301.40 million in 2025, 21.0% share, 9.4% CAGR, offering niche PV analytics services.
• China: USD 258.34 million in 2025, 18.0% share, 9.8% CAGR, with rising PV tech startups.
• Germany: USD 200.93 million in 2025, 14.0% share, 9.5% CAGR, in specialty drug safety consulting.
• Japan: USD 157.88 million in 2025, 11.0% share, 9.6% CAGR, focusing on post-market safety for rare diseases.
• India: USD 143.52 million in 2025, 10.0% share, 9.9% CAGR, expanding with low-cost PV support solutions.

Pharmacovigilance and Drug Safety Software Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates with 41% market share, exceeding 19,500 installations in 2024. The USA leads with 86% of the regional total, driven by FDA mandates for electronic submissions. Canada accounts for 9%, and Mexico 5%. Cloud adoption in the region reached 64% in 2024.. High adoption rates are seen across contract research organizations (CROs), pharmaceutical companies, and biotech firms, where end-to-end safety case management systems and real-time analytics platforms are critical for compliance and operational efficiency.

North America’s pharmacovigilance and drug safety software market is valued at USD 6,061.64 million in 2025, representing 38.0% of the global share, and is projected to grow at a steady 9.1% CAGR through 2034. The region’s dominance is driven by a mature pharmaceutical and biotechnology industry, advanced healthcare IT integration, and stringent FDA pharmacovigilance guidelines that mandate comprehensive adverse event monitoring and reporting.

North America – Major Dominant Countries in the Pharmacovigilance and Drug Safety Software Market

• United States: With a valuation of USD 4,849.31 million in 2025, holding 80.0% of the regional share and growing at 9.0% CAGR, the US leads through extensive deployment of integrated safety case management platforms, global regulatory submission tools, and AI-driven pharmacovigilance analytics.
• Canada: Estimated at USD 424.32 million in 2025, with a 7.0% share and 9.2% CAGR, the Canadian market benefits from government-backed drug safety monitoring programs, expanding adoption in clinical research, and strong healthcare IT infrastructure.
• Mexico: Valued at USD 303.08 million in 2025, accounting for 5.0% of the market and expanding at 9.4% CAGR, Mexico is witnessing growth in pharmacovigilance outsourcing for clinical trials and pharmaceutical manufacturing operations.
• Puerto Rico: At USD 181.79 million in 2025, with a 3.0% share and 9.1% CAGR, Puerto Rico’s market is primarily driven by manufacturing-linked compliance requirements and the presence of large-scale drug production facilities.
• Dominican Republic: Matching Puerto Rico at USD 181.79 million in 2025, with 3.0% share and 9.0% CAGR, the Dominican Republic is expanding its pharmacovigilance capacity through investments in hospital-based safety monitoring and pharma-linked healthcare networks.

EUROPE

Europe holds 30% share, with 14,300 installations across 27 countries. The UK leads with 22%, Germany with 18%, and France with 14%. EU pharmacovigilance regulations require all MAHs (Marketing Authorization Holders) to maintain an EudraVigilance-compatible database.

Europe’s market is valued at USD 4,307.31 million in 2025, holding 27.0% of the global share, with a projected CAGR of 9.0% through 2034. The region benefits from EU-wide drug safety directives, a robust network of pharmaceutical hubs, and the mandatory use of EudraVigilance for centralized adverse event reporting. High adoption rates are driven by compliance demands, advanced clinical trial oversight, and digital transformation initiatives in healthcare that integrate pharmacovigilance workflows with hospital, research, and manufacturing systems.

Europe – Major Dominant Countries in the Pharmacovigilance and Drug Safety Software Market

• Germany: At USD 1,118.90 million in 2025, holding 26.0% share and growing at 8.9% CAGR, Germany dominates with widespread use of PV systems in both domestic and multinational pharmaceutical operations, supported by a strong manufacturing base and clinical research capacity.
• United Kingdom: Valued at USD 947.61 million in 2025, with a 22.0% share and 9.0% CAGR, the UK’s growth is led by CRO-linked pharmacovigilance expansion, cloud-based safety platforms, and increased clinical trial outsourcing.
• France: Estimated at USD 775.32 million in 2025, capturing 18.0% share and growing at 8.8% CAGR, France is advancing PV adoption through hospital-linked safety programs, government monitoring initiatives, and strong ties with biotech innovators.
• Italy: At USD 646.10 million in 2025, representing 15.0% share with a 9.1% CAGR, Italy’s market is supported by growth in the life sciences sector, regulatory compliance investments, and increasing participation in multinational drug trials.
• Spain: Valued at USD 560.00 million in 2025, holding 13.0% share and growing at 9.0% CAGR, Spain benefits from digital health initiatives and pharmacovigilance system integration in national healthcare networks.

ASIA-PACIFIC

Asia-Pacific has 23% share, with 11,000 installations in 2024. Japan holds 29% of regional demand, China 27%, and India 21%. Rising clinical trial volumes in the region—over 8,400 in 2024—are driving adoption. Integration of PV systems with hospital networks and the growing outsourcing of drug safety processes to CROs and BPOs contribute to the region’s accelerating adoption. 

Asia’s pharmacovigilance and drug safety software market is projected at USD 4,307.31 million in 2025, representing 27.0% of the global share, and is forecast to grow at the fastest rate of 9.6% CAGR through 2034. The rapid expansion is driven by increasing clinical trial activity, booming domestic pharmaceutical manufacturing, and government-backed pharmacovigilance systems in countries such as China, India, and Japan. Integration of PV systems with hospital networks and the growing outsourcing of drug safety processes to CROs and BPOs contribute to the region’s accelerating adoption.

Asia – Major Dominant Countries in the Pharmacovigilance and Drug Safety Software Market

• China: At USD 1,938.29 million in 2025, holding 45.0% share and growing at 9.7% CAGR, China leads with large-scale PV automation in manufacturing, distribution, and national drug monitoring programs.
• India: Valued at USD 1,120.90 million in 2025, with a 26.0% share and 9.9% CAGR, India’s market is propelled by rapid CRO and BPO expansion, supported by central pharmacovigilance centers and outsourced safety data processing.
• Japan: Estimated at USD 861.46 million in 2025, holding 20.0% share and growing at 9.5% CAGR, Japan’s adoption is advanced by high-tech hospital-linked PV systems and integration with nationwide healthcare IT.
• South Korea: At USD 301.51 million in 2025, representing 7.0% share and 9.6% CAGR, South Korea’s market is strengthened by biotech-led safety management and automation in drug safety reporting.
• Indonesia: Valued at USD 215.37 million in 2025, with a 5.0% share and 9.7% CAGR, Indonesia is expanding PV adoption through emerging clinical research hubs and increased regulatory oversight.

MIDDLE EAST & AFRICA

MEA accounts for 6% share, with 3,100 active systems. The UAE leads with 34% of regional demand, followed by South Africa at 28%. Regulatory modernization programs in Saudi Arabia and Egypt are boosting adoption.

The Middle East and Africa market is valued at USD 1,276.73 million in 2025, accounting for 8.0% of global share, and is expected to grow at 9.1% CAGR through 2034. This growth is underpinned by strong pharmaceutical investments in the GCC, modernization of regulatory frameworks, and integration of PV systems in private and public healthcare facilities. Adoption is also increasing in clinical trial monitoring, especially in emerging research centers.

Middle East and Africa – Major Dominant Countries in the Pharmacovigilance and Drug Safety Software Market

• Saudi Arabia: At USD 383.02 million in 2025, with 30.0% share and 9.0% CAGR, Saudi Arabia leads in pharma manufacturing-linked safety compliance and centralized drug safety systems.
• UAE: Valued at USD 306.42 million in 2025, holding 24.0% share and growing at 9.2% CAGR, the UAE market is characterized by PV integration into luxury healthcare facilities and research institutions.
• South Africa: Estimated at USD 217.04 million in 2025, with a 17.0% share and 8.9% CAGR, South Africa benefits from adoption in private hospitals, research labs, and multinational pharma branches.
• Egypt: At USD 153.21 million in 2025, with a 12.0% share and 8.8% CAGR, Egypt’s adoption is growing through university hospital systems and national drug safety programs.
• Nigeria: Valued at USD 127.67 million in 2025, holding 10.0% share and growing at 9.0% CAGR, Nigeria is seeing PV expansion in corporate healthcare networks and pharma-led safety initiatives.

List of Top Pharmacovigilance and Drug Safety Software Companies

• Aris Global
• Relays
• EXTEDO GmbH
• Sparta Systems, Inc.
• Sarjen Systems Pvt. Ltd
• Max Delivery
• Online Business Applications, Inc.
• United BioSource Corporation
• Oracle Corporation
• Ennov Solutions Inc.
• AB Cube

Top Two Companies with the Highest Share

ArisGlobal: Holds 16% global share, with over 7,000 installations in 115 countries.

Oracle Corporation: Holds 14% share, with over 6,200 deployments, including 90% of top 20 global pharma companies.

Investment Analysis and Opportunities

Between 2023 and 2024, the pharmacovigilance and drug safety software sector attracted over USD 1.8 billion in combined investments directed toward research, development, and infrastructure expansion. These funds have been channeled into scaling advanced safety case management systems, improving regulatory compliance modules, and building next-generation cloud hosting capabilities for large-scale pharmaceutical operations. Emerging economies across Asia-Pacific and Latin America are showing exceptional growth potential, with adoption rates increasing at an average of 18% annually, supported by expanding clinical trial activity, government safety mandates, and increased outsourcing to regional CROs and BPOs. Among investment trends, AI-driven safety signal detection has emerged as the fastest-growing segment, securing 38% of new funding allocations. This surge is driven by the ability of AI algorithms to rapidly identify, categorize, and escalate potential adverse events, significantly reducing manual review timelines and enhancing the accuracy of pharmacovigilance reporting worldwide.

New Product Development

In 2024, innovation in pharmacovigilance software centered around automation, accessibility, and global compliance, with over 60% of new launches integrating machine learning-based case prioritization tools. These systems are designed to streamline adverse event triage, automatically rank cases by severity, and ensure that high-risk reports are reviewed first, improving both efficiency and patient safety outcomes. Cloud-first pharmacovigilance platforms are now being designed with multi-language support, enabling simultaneous reporting and regulatory submissions in multiple jurisdictions—a key capability for multinational pharmaceutical companies and global CROs. Mobile-based ADR (Adverse Drug Reaction) reporting solutions have become a critical innovation segment, currently adopted by over 2 million healthcare professionals worldwide, allowing real-time adverse event capture directly from clinical settings. This mobile accessibility improves case completeness, accelerates reporting timelines, and enables more comprehensive data collection from regions with previously limited pharmacovigilance infrastructure.

Five Recent Developments

• 2025 – Aris Global released an AI-driven case intake module, reducing processing time by 32%.
• 2024 – Oracle launched a cloud-native signal management tool integrated with real-world evidence databases.
• 2024 – EXTEDO introduced a Surveillance 2.0-compliant submission suite.
• 2023 – Sparta Systems upgraded its Track Wise Digital platform with advanced audit trail analytics.
• 2023 – Ennov Solutions deployed a pharmacovigilance platform for 120 hospitals in France.

Report Coverage of Pharmacovigilance and Drug Safety Software Market

The Pharmacovigilance and Drug Safety Software Market Report covers global adoption trends, technological innovations, and regulatory impacts across 40+ countries. It analyzes type and application segments, profiles 20 major vendors, and includes data on over 60,000 active deployments. The report tracks investments, product launches, and regional market shifts from 2015 to 2024, offering forecasts up to 2030.

The report segments the market by type—ADR reporting software, drug safety audit software, issue tracking software, and fully integrated solutions—and by application, including pharma and biotech companies, CROs, BPOs, and other pharmacovigilance service providers. It reveals that fully integrated solutions account for 46% of all installations globally, while ADR reporting systems handle more than 1.2 billion safety cases annually.

Pharmacovigilance and Drug Safety Software Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 17439.81 Million in 2026
Market Size Value By	USD 38887.68 Million by 2035
Growth Rate	CAGR of 9.32% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : ADR Reporting Software Drug Safety Audits Software Issue Tracking Software Fully Integrated Software By Application : Pharma and Biotech Companies Contract Research Organizations (CROs) Business Process Outsourcing (BPO) Firms Other Pharmacovigilance Service Providers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample